article thumbnail

EMA human medicines committee (CHMP) highlights, November 2022

European Pharmaceutical Review

CHMP’s safety update. The CHMP endorsed measures recommended by the EMA Pharmacovigilance Risk Assessment Committee (PRAC), to minimise the risk of serious side effects (cardiovascular conditions, blood clots, cancer and serious infections) of janus kinase (JAK) inhibitors for treating several chronic inflammatory disorders.

article thumbnail

Cell therapies might revolutionise treatment for multiple sclerosis patients

Pharmaceutical Technology

While the treatment options for multiple sclerosis (MS) patients are growing each year with the approval of new agents, all of the currently marketed treatments only slow the disease’s progression and sometimes carry risks of severe side effects, such as liver failure or the development of viral infections.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Navigating the Regulatory Environment of Pharmaceutical Marketing: Balancing Patient Safety and Industry Innovation

Pharma Marketing Network

Pharmaceutical marketing is a critical aspect of the industry, as it helps in spreading awareness about the benefits and potential side effects of different drugs. In conclusion, navigating the regulatory environment of pharmaceutical marketing requires a delicate balance between patient safety and industry innovation.

Safety 52
article thumbnail

EMA’s PRAC confirms recommendation to withdraw amfepramones

European Pharmaceutical Review

The Pharmacovigilance Risk Assessment Committee (PRAC) , the European Medicines Agency (EMA)’s safety board, has confirmed it recommends the withdrawal of Marketing Authorisation Application (MAA) for amfepramone obesity medicines, to prevent more patients being at risk of serious side effects. Risks of amfepramones.

article thumbnail

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

The FDA said its approval of Wezlana is based on “a comprehensive review of scientific evidence demonstrating it is highly similar to Stelara and that there are no clinically meaningful differences between the two products in terms of safety, purity and potency.” Like Stelara, the most serious known side effect of Wezlana is infection.

article thumbnail

UK approves Moderna’s bivalent COVID-19 vaccine

European Pharmaceutical Review

The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. Safety monitoring showed that the side effects observed were the same as those seen for the original Moderna booster dose and were typically mild and self-resolving. No serious safety concerns were identified.

Safety 99
article thumbnail

Two Key Questions About Adherence/Compliance in 2022

PM360

Accordingly, multiple reasons for subpar patient adherence are gaining attention, including fear of side effects, lack of medical understanding, or even financial limitations. Measuring and monitoring adherence in clinical trials would add valuable information about the effectiveness and safety of drugs.

Medical 105